It is important to note that highly bortezomib-resistant MM cells (PS-R) exposed to CDK inhibitors (e.g., dinaciclib or alvocidib) exhibited marked disruption of P-TEFb activation, reductions in Mcl-1 expression comparable to those of bortezomib-sensitive cells, and equivalent degrees of cell death. This evidence concerns the gene MCL1 and Miyoshi myopathy.